Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR 270.55
+10.20 (3.92%)
At close: Sep 4, 2026
Medicamen Biotech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 3,440 | 2,856 | 6,125 | 4,871 | 8,293 | 7,864 | |
Market Cap Growth | -23.02% | -53.36% | 25.74% | -41.27% | 5.46% | 20.54% |
Enterprise Value | 3,605 | 2,806 | 6,262 | 5,027 | 8,273 | 8,078 |
Last Close Price | 270.55 | 224.65 | 480.26 | 381.13 | 651.22 | 638.84 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 36.32 | 29.63 | 86.16 | 44.56 | 55.87 | 52.79 |
PS Ratio | 1.67 | 1.42 | 3.66 | 2.72 | 5.89 | 6.81 |
PB Ratio | 1.25 | 1.04 | 2.88 | 2.35 | 4.29 | 5.37 |
P/TBV Ratio | 1.25 | 1.04 | 2.90 | 2.38 | 4.34 | 5.38 |
P/OCF Ratio | - | - | - | - | - | 191.38 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.75 | 1.40 | 3.74 | 2.80 | 5.87 | 7.00 |
EV/EBITDA Ratio | 15.75 | 12.36 | 33.48 | 22.67 | 34.63 | 34.27 |
EV/EBIT Ratio | 23.11 | 18.13 | 53.10 | 32.95 | 46.92 | 45.14 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.17 | 0.17 | 0.16 | 0.15 | 0.13 | 0.18 |
Debt / EBITDA Ratio | 2.09 | 2.10 | 1.81 | 1.40 | 1.08 | 1.09 |
Net Debt / Equity Ratio | 0.06 | 0.06 | 0.14 | 0.08 | 0.03 | 0.15 |
Net Debt / EBITDA Ratio | 0.72 | 0.73 | 1.61 | 0.74 | 0.21 | 0.93 |
Net Debt / FCF Ratio | - | -0.43 | -2.90 | -1.25 | -0.38 | -4.88 |
Asset Turnover | - | 0.60 | 0.57 | 0.63 | 0.56 | 0.55 |
Inventory Turnover | - | 1.54 | 1.42 | 1.80 | 2.04 | 3.37 |
Quick Ratio | - | 1.29 | 1.25 | 1.09 | 1.31 | 1.19 |
Current Ratio | - | 2.55 | 2.11 | 1.89 | 1.98 | 1.69 |
Return on Equity (ROE) | - | 4.01% | 3.12% | 4.74% | 8.67% | 10.67% |
Return on Assets (ROA) | - | 2.89% | 2.49% | 3.33% | 4.37% | 5.33% |
Return on Invested Capital (ROIC) | 4.32% | 4.73% | 3.36% | 5.25% | 8.31% | 9.32% |
Return on Capital Employed (ROCE) | - | 5.50% | 5.40% | 7.30% | 9.00% | 11.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.79% | 3.38% | 1.16% | 2.24% | 1.79% | 1.89% |
FCF Yield | -11.03% | -13.29% | -1.69% | -2.67% | -1.55% | -0.57% |
Dividend Yield | 0.38% | 0.45% | 0.21% | 0.26% | 0.15% | 0.16% |
Payout Ratio | - | 14.07% | 17.89% | 11.57% | 8.52% | 8.20% |
Buyback Yield / Dilution | -8.24% | -6.67% | -0.44% | -0.07% | -3.56% | - |
Total Shareholder Return | -7.85% | -6.23% | -0.23% | 0.20% | -3.40% | 0.16% |